亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Glaucoma Blockbuster

技术优势: Increased aqueous outflow from the eye Lowering of intraocular pressure Vision preservation

详细技术说明: Glaucoma is a family of irreversible eye diseases characterized by an increase in intraocular pressure that if left untreated, can permanently damage the optic nerve and lead to blindness. It is estimated that glaucoma will affect 79.6 million people worldwide by the year 2020. The increase in intraocular pressure is due to an increased resistance to the outflow of the “aqueous humor” through the primary drain of the eye, called the “trabecular meshwork”. This results in an increase in intraocular pressure, and if left untreated, can cause a gradual loss of vision, and eventually permanent blindness. Currently, the only rigorously validated treatment for patients with glaucoma is therapeutically lowering intraocular pressure. These therapeutic agents however, simply prevent vision loss, and do not target the primary drainage pathway from the eye, and instead target a secondary outflow site to aqueous humor called the uveoscleral pathway. Researchers at the University of California, Davis have developed a novel therapy to treat glaucoma by targeting the primary drainage pathway from the eye, the “trabecular meshwork”. The novel treatment functions by modulating the stiffness of the trabecular meshwork. This treatment not only stops the progression of glaucoma, but also alleviates intraocular pressure and preserves a patient’s vision.

*Abstract: Glaucoma is a devastating condition that can lead to loss of sight. This is estimated to affect nearly 79.6 million people worldwide by the year 2020. While there are some treatments that help to prevent vision loss, there are no treatments to correct the condition, until now. Researchers at the University of California, Davis have determined a novel class of compounds that are effective in the treatment of glaucoma.

*Principal Investigation: Name: Joshua Morgan
Department:

Name: Christopher Murphy
Department:

Name: Vijay Raghunathan
Department:

Name: Paul Russell
Department:

Name: Sara Thomasy
Department:

Name: Joshua Wood
Department:

其他

Additional Technologies by these Inventors

Tech ID/UC Case

24232/2013-196-0

Related Cases

2013-196-0

欲了解更多信息，请点击这里